Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -75.79% is in line with its 5-year average of -69.97%, around the middle of its 5-year range (-120.98%–-27.04%).
As of the fiscal period ended Tuesday, June 30, 2026. 21.20% below its 12-month average of -62.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2027 (2026-06-30): -75.79%.
RETURN ON EQUITY (ROE)
-75.79%
RETURN ON EQUITY (ROE) AVG TTM
-62.54%
RETURN ON EQUITY (ROE) AVG 3Y
-55.77%
RETURN ON EQUITY (ROE) AVG 5Y
-69.97%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-21.20%
CURRENT VS 3Y AVG
-35.91%
CURRENT VS 5Y AVG
-8.32%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 686 covered companies
CURRENT VS SECTOR MEDIAN
-85.36%
vs the sector median at left
Helus Pharma Inc.
Market Cap
$673.15M
Return on Equity (ROE)
-75.79%
TTM Avg
-62.54%
3Y Avg
-55.77%
5Y Avg
-69.97%
Market Cap
$674.21M
Return on Equity (ROE)
-108.93%
TTM Avg
-72.41%
3Y Avg
-64.95%
5Y Avg
-55.74%
Market Cap
$668.57M
Return on Equity (ROE)
2.89%
TTM Avg
20.45%
3Y Avg
11.91%
5Y Avg
-3.26%
Market Cap
$665.51M
Return on Equity (ROE)
-43.95%
TTM Avg
-29.61%
3Y Avg
-34.61%
5Y Avg
-30.48%
Market Cap
$682.75M
Return on Equity (ROE)
-55.36%
TTM Avg
-93.85%
3Y Avg
-76.06%
5Y Avg
-67.62%
Market Cap
$657.89M
Return on Equity (ROE)
N/A
TTM Avg
385.53%
3Y Avg
385.53%
5Y Avg
385.53%
Market Cap
$693.75M
Return on Equity (ROE)
-41.20%
TTM Avg
50554.28%
3Y Avg
25132.94%
5Y Avg
16622.35%
Market Cap
$648.75M
Return on Equity (ROE)
-17.01%
TTM Avg
-22.91%
3Y Avg
-17.12%
5Y Avg
-14.58%
Market Cap
$701.75M
Return on Equity (ROE)
-22.36%
TTM Avg
-60.32%
3Y Avg
-42.71%
5Y Avg
-132.49%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Helus Pharma Inc. (HELP) | $673.15M | -75.79% | -62.54% | -55.77% | -69.97% |
| Annexon, Inc. (ANNX)vs › | $674.21M | -108.93% | -72.41% | -64.95% | -55.74% |
| MiMedx Group, Inc. (MDXG)vs › | $668.57M | 2.89% | 20.45% | 11.91% | -3.26% |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $665.51M | -43.95% | -29.61% | -34.61% | -30.48% |
| Solid Biosciences Inc. (SLDB)vs › | $682.75M | -55.36% | -93.85% | -76.06% | -67.62% |
| Starling Oncology, Inc. (STLN)vs › | $657.89M | N/A | 385.53% | 385.53% | 385.53% |
| Anteris Technologies Global Corp. (AVR)vs › | $693.75M | -41.20% | 50554.28% | 25132.94% | 16622.35% |
| OmniAb, Inc. (OABI)vs › | $648.75M | -17.01% | -22.91% | -17.12% | -14.58% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $701.75M | -22.36% | -60.32% | -42.71% | -132.49% |
| Olema Pharmaceuticals, Inc. (OLMA)vs › | $706.51M | -47.51% | -32.80% | -39.18% | -31.37% |
ROE
-75.8%
ROA
-70.7%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -75.79% |
| 2026-03-31 | -49.89% |
| 2025-12-31 | -49.51% |
| 2025-09-30 | -51.80% |
| 2025-06-30 | -85.68% |
| 2025-03-31 | -47.78% |
| 2024-12-31 | -43.90% |
| 2024-09-30 | -47.03% |
| 2024-06-30 | -27.04% |
| 2024-03-31 | -27.04% |
| 2023-12-31 | -57.65% |
| 2023-09-30 | -106.05% |
| 2023-06-30 | -120.98% |
| 2023-03-31 | -99.29% |
| 2022-12-31 | -95.62% |
| 2022-09-30 | -97.84% |
| 2022-06-30 | -98.38% |
| 2022-03-31 | -88.41% |
| 2021-12-31 | -71.43% |
| 2021-09-30 | -58.29% |
| 2019-01-31 | -26.88% |
| 2018-07-31 | -52.39% |
